185 related articles for article (PubMed ID: 31098997)
1. Combinatorial siRNA Polyplexes for Receptor Targeting.
Lee DJ; Wagner E
Methods Mol Biol; 2019; 1974():83-98. PubMed ID: 31098997
[TBL] [Abstract][Full Text] [Related]
2. Tumoral gene silencing by receptor-targeted combinatorial siRNA polyplexes.
Lee DJ; He D; Kessel E; Padari K; Kempter S; Lächelt U; Rädler JO; Pooga M; Wagner E
J Control Release; 2016 Dec; 244(Pt B):280-291. PubMed ID: 27287890
[TBL] [Abstract][Full Text] [Related]
3. Post-PEGylation of siRNA Lipo-oligoamino Amide Polyplexes Using Tetra-glutamylated Folic Acid as Ligand for Receptor-Targeted Delivery.
Müller K; Kessel E; Klein PM; Höhn M; Wagner E
Mol Pharm; 2016 Jul; 13(7):2332-45. PubMed ID: 27177200
[TBL] [Abstract][Full Text] [Related]
4. Sequence-defined oligoaminoamides for the delivery of siRNAs.
Lee DJ; Wagner E; Lehto T
Methods Mol Biol; 2015; 1206():15-27. PubMed ID: 25240883
[TBL] [Abstract][Full Text] [Related]
5. Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand.
Lee DJ; Kessel E; Edinger D; He D; Klein PM; Voith von Voithenberg L; Lamb DC; Lächelt U; Lehto T; Wagner E
Biomaterials; 2016 Jan; 77():98-110. PubMed ID: 26584350
[TBL] [Abstract][Full Text] [Related]
6. Zwitterionic Nanocarrier Surface Chemistry Improves siRNA Tumor Delivery and Silencing Activity Relative to Polyethylene Glycol.
Jackson MA; Werfel TA; Curvino EJ; Yu F; Kavanaugh TE; Sarett SM; Dockery MD; Kilchrist KV; Jackson AN; Giorgio TD; Duvall CL
ACS Nano; 2017 Jun; 11(6):5680-5696. PubMed ID: 28548843
[TBL] [Abstract][Full Text] [Related]
7. Targeted decationized polyplexes for siRNA delivery.
Novo L; Takeda KM; Petteta T; Dakwar GR; van den Dikkenberg JB; Remaut K; Braeckmans K; van Nostrum CF; Mastrobattista E; Hennink WE
Mol Pharm; 2015 Jan; 12(1):150-61. PubMed ID: 25384057
[TBL] [Abstract][Full Text] [Related]
8. Hydrophobic interactions between polymeric carrier and palmitic acid-conjugated siRNA improve PEGylated polyplex stability and enhance in vivo pharmacokinetics and tumor gene silencing.
Sarett SM; Werfel TA; Chandra I; Jackson MA; Kavanaugh TE; Hattaway ME; Giorgio TD; Duvall CL
Biomaterials; 2016 Aug; 97():122-32. PubMed ID: 27163624
[TBL] [Abstract][Full Text] [Related]
9. Revisiting the value of competition assays in folate receptor-mediated drug delivery.
Jones SK; Sarkar A; Feldmann DP; Hoffmann P; Merkel OM
Biomaterials; 2017 Sep; 138():35-45. PubMed ID: 28551461
[TBL] [Abstract][Full Text] [Related]
10. Efficient and Tumor Targeted siRNA Delivery by Polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol)-folate (PEI-PCL-PEG-Fol).
Liu L; Zheng M; Librizzi D; Renette T; Merkel OM; Kissel T
Mol Pharm; 2016 Jan; 13(1):134-43. PubMed ID: 26641134
[TBL] [Abstract][Full Text] [Related]
11. To Conjugate or to Package? A Look at Targeted siRNA Delivery Through Folate Receptors.
Salim L; Desaulniers JP
Nucleic Acid Ther; 2021 Feb; 31(1):21-38. PubMed ID: 33121373
[TBL] [Abstract][Full Text] [Related]
12. Systemic Delivery of Folate-PEG siRNA Lipopolyplexes with Enhanced Intracellular Stability for In Vivo Gene Silencing in Leukemia.
Lee DJ; Kessel E; Lehto T; Liu X; Yoshinaga N; Padari K; Chen YC; Kempter S; Uchida S; Rädler JO; Pooga M; Sheu MT; Kataoka K; Wagner E
Bioconjug Chem; 2017 Sep; 28(9):2393-2409. PubMed ID: 28772071
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial optimization of PEG architecture and hydrophobic content improves ternary siRNA polyplex stability, pharmacokinetics, and potency in vivo.
Werfel TA; Jackson MA; Kavanaugh TE; Kirkbride KC; Miteva M; Giorgio TD; Duvall C
J Control Release; 2017 Jun; 255():12-26. PubMed ID: 28366646
[TBL] [Abstract][Full Text] [Related]
14. Enhanced gene silencing through human serum albumin-mediated delivery of polyethylenimine-siRNA polyplexes.
Nicolì E; Syga MI; Bosetti M; Shastri VP
PLoS One; 2015; 10(4):e0122581. PubMed ID: 25856158
[TBL] [Abstract][Full Text] [Related]
15. Transferrin Receptor Targeted Polyplexes Completely Comprised of Sequence-Defined Components.
Benli-Hoppe T; Göl Öztürk Ş; Öztürk Ö; Berger S; Wagner E; Yazdi M
Macromol Rapid Commun; 2022 Jun; 43(12):e2100602. PubMed ID: 34713524
[TBL] [Abstract][Full Text] [Related]
16. Strategies for in vivo siRNA delivery in cancer.
Sanguino A; Lopez-Berestein G; Sood AK
Mini Rev Med Chem; 2008 Mar; 8(3):248-55. PubMed ID: 18336345
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor targeted methotrexate and small interfering RNA co-delivery.
Steinborn B; Truebenbach I; Morys S; Lächelt U; Wagner E; Zhang W
J Gene Med; 2018 Jul; 20(7-8):e3041. PubMed ID: 29949222
[TBL] [Abstract][Full Text] [Related]
18. Nanosized multifunctional polyplexes for receptor-mediated siRNA delivery.
Dohmen C; Edinger D; Fröhlich T; Schreiner L; Lächelt U; Troiber C; Rädler J; Hadwiger P; Vornlocher HP; Wagner E
ACS Nano; 2012 Jun; 6(6):5198-208. PubMed ID: 22646997
[TBL] [Abstract][Full Text] [Related]
19. Systemic delivery of siRNA by aminated poly(α)glutamate for the treatment of solid tumors.
Polyak D; Krivitsky A; Scomparin A; Eliyahu S; Kalinski H; Avkin-Nachum S; Satchi-Fainaro R
J Control Release; 2017 Jul; 257():132-143. PubMed ID: 27356019
[TBL] [Abstract][Full Text] [Related]
20. Native chemical ligation for conversion of sequence-defined oligomers into targeted pDNA and siRNA carriers.
Zhang CY; Kos P; Müller K; Schrimpf W; Troiber C; Lächelt U; Scholz C; Lamb DC; Wagner E
J Control Release; 2014 Apr; 180():42-50. PubMed ID: 24566255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
